Tango Therapeutics
BOSTON, MA · Healthcare, Health Care · 169 employees
Tango Therapeutics is a clinical-stage biotechnology company pioneering the next generation of precision cancer medicines. Founded in 2017 with a $55 million Series A investment from Third Rock Ventures, the company leverages advances in DNA sequencing and CRISPR-based target discovery to develop breakthrough therapies with deeper, more durable benefits than current treatments. Focused on three ke
Funding history
- Funding Round — $15.0M — Oct 2025
- Funding Round — $80.0M — Aug 2023
- Series series b — $60.0M — Apr 2020
Recent signals
- Apr 15, 2026: Tango Therapeutics Appoints Matthew Gall as Chief Financial Officer
- Oct 28, 2025: Raised $15.0M
- Oct 23, 2025: SEC 8-K (1.01): On October 23, 2025, Tango Therapeutics, Inc. entered into an Underwriting Agreement with Leerink Partners LLC for a Registered Direct Offering. This agreement involves the sale of 21,023,337 shares of the Company's common stock and pre-funded warrants for an additional 3,226,458 shares. This sale marks a significant capital raise for the company, indicated by the size of the offering. The financial and strategic implications include increased liquidity for the company, potentially allowing for further research and development activities. Specific offering prices were not detailed in the provided content.
- Nov 06, 2024: Launched Tango Therapeutics Announces Update on TNG462 and Introduction of TNG456 for Cancer Treatment.
- Aug 24, 2023: Raised $80.0M
- Apr 09, 2020: Raised $60.0M in Series series b
See plans & pricing → Track Tango Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.